Not Finding What You're Looking For?
Effects of twice-daily dosing 4-AP on Functional Recovery after Spinal Cord Injury
Our studies aim to investigate potential Neuro-modulation Therapies with the help of an FDA approved drug in individuals with spinal cord injuries.
Age Range
18-85
Clinical Trial
The Benefits of Recreation Therapy in Inpatient Rehabilitation
After a life-changing injury or illness, many people choose to continue their recovery in an inpatient rehabilitation hospital like Shirley Ryan AbilityLab — to restore function, recover lost abilities and regain independence.
Blog
Adaptive Kayaking
What a better way to spend your afternoon than exploring nature, all while gliding through the water. Several types of adaptations made available ensure you're in for comfortable and safe ride.
Page
Nick’s Story: How Assistive Technology Gave Him a Voice
Nick lost the ability to communicate at just 17 years old when his heart stopped during a routine surgery on his jaw. He went without oxygen for 10 minutes, leaving him with a severe brain injury and unable to walk, talk or eat.
Patient Story
IEEE Spectrum Feature on Self-Balancing Exoskeleton
In a recent article in IEEE Spectrum on a self-balancing exoskeleton by Human in Motion Robotics, Arun Jayaraman, PT, PhD, Director of the Max Näder Center for Rehabilitation Technologies and Outcomes Research, provided insights on at-home use of self-balancing exoskeletons.
In the News
Shirley Ryan AbilityLab Physical Therapist Shares Insights in The New York Times about Pain & Exercise
Shirley Ryan AbilityLab’s Conor O’Donovan, DPT — a physical therapist in the rehabilitation hospital’s Pain Management Center — shared his expertise about pain and exercise in a recent article by The New York Times, Your Workout Should Hurt. But When is Pain a Red Flag?
News
Brain-Based and Clinical Phenotyping of Pain Pharmacotherapy in Knee Osteoarthritis (PREDICT)
This is a clinical trial of people who have pain due to knee osteoarthritis at Northwestern University Feinberg School of Medicine in collaboration with Shirley Ryan AbilityLab. The study will last for about 20 weeks. 180 qualified participants will be randomly assigned in a 1:1:1 ratio (60 participants per group) to one of three treatment groups: duloxetine, celecoxib or placebo. Participants will have an X-ray, knee MRI, brain MRI, blood draws, pain sensitivity testing and will be asked to fill out questionnaires. The purpose of this study is to predict which participants will respond to the treatment.
Age Range
40-99
Clinical Trial
Impact Series Spotlight: Aphasia Community Groups
The Center for Aphasia Research and Treatment offers programs that give participants the opportunity to practice communication, meet others living with aphasia, learn and have fun in a supportive environment.
In the News
Neural Prosthesis Seminar Series with Guest Speaker Dr. Arun Jayaraman
The Cleveland FES Center’s Neural Prosthesis Seminar Series welcomes Dr. Arun Jayaraman to discuss Innovations in Wearables, Machine Learning, and Automation.
In the News
Former Shirley Ryan AbilityLab Patient Utilizes New Device for Spinal Cord Stimulation
Former Shirley Ryan AbilityLab patient, Shane Callahan, who has a spinal cord injury, is using the new ARC-EX device at Next Steps Chicago. Read the full feature in the Chicago Tribune.
In the News
